The Jewish General Hospital, known officially as the Sir Mortimer B. Davis Jewish General Hospital since 1978, is an acute-care teaching hospital in Montreal, Quebec, Canada. The hospital is affiliated with McGill University and has 637 beds, one of the most of a hospital site in Canada.

There are 637 beds in Jewish General Hospital; Clinical Research Unit.

During the past decade, Jewish General Hospital; Clinical Research Unit conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Jewish General Hospital; Clinical Research Unit" #1 sponsor was "Aravive, Inc." with 1 trials, followed by "CTI BioPharma" with 1 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored, "Jewish General Hospital" with 1 trials sponsored and "Ocellaris Pharma, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Jewish General Hospital; Clinical Research Unit" #1 collaborator was "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator, "GOG Foundation" with 1 trials as a collaborator and "PSI CRO" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Jewish General Hospital; Clinical Research Unit" are "Cancer" (2 trials), "Bladder Cancer" (1 trials), "Cervical Cancer" (1 trials), "Gastric Cancer" (1 trials) and "Hepatocellular Carcinoma" (1 trials). Many other conditions were trialed in "Jewish General Hospital; Clinical Research Unit" in a lesser frequency.

Most popular intervention types in "Jewish General Hospital; Clinical Research Unit" are "Drug" (4 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Batiraxcept" (1 trials), "Bevacizumab" (1 trials), "Cetuximab" (1 trials) and "FOLFOX" (1 trials). Other intervention names were less common.

The vast majority of trials in "Jewish General Hospital; Clinical Research Unit" are 4 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Jewish General Hospital; Clinical Research Unit". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Jewish General Hospital; Clinical Research Unit, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Jewish General Hospital; Clinical Research Unit, 3 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".